Kyle Gano - 15 Jan 2025 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Role
Chief Executive Officer, Director
Signature
/s/ Darin Lippoldt, Attorney-in-Fact
Issuer symbol
NBIX
Transactions as of
15 Jan 2025
Transactions value $
-$7,053,200
Form type
4
Filing time
17 Jan 2025, 16:32:00 UTC
Previous filing
01 Nov 2024
Next filing
04 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBIX Common Stock Options Exercise $158,747 +4,812 +3.6% $32.99 140,204 15 Jan 2025 Direct
transaction NBIX Common Stock Sale -$680,893 -4,812 -3.4% $141.5 135,392 15 Jan 2025 Direct F1, F2
transaction NBIX Common Stock Options Exercise $1,985,602 +60,188 +44% $32.99 195,580 15 Jan 2025 Direct
transaction NBIX Common Stock Sale -$8,516,656 -60,188 -31% $141.5 135,392 15 Jan 2025 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NBIX Incentive Stock Option Options Exercise $0 -4,812 -100% $0 0 15 Jan 2025 Common Stock 4,812 $32.99 Direct F4
transaction NBIX Non-Qualified Stock Option Options Exercise $0 -60,188 -100% $0 0 15 Jan 2025 Common Stock 60,188 $32.99 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
F2 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $139.53 to $142.62. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3 Includes an aggregate of 226 shares purchased on February 29, 2024, from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.
F4 The option was granted February 3, 2015 and vested in 48 equal monthly installments beginning on March 3, 2015. These options were due to expire on February 3, 2025.